A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Trial details
- Registry ID
- NCT07656415
- Phase
- Phase 3
The PDUFA goal date for Mitapivat (AG-348) in sickle cell disease is 1 Feb 2027, as disclosed by Agios Pharmaceuticals, Inc. (AGIO).
Drug identity checked against registry records
Also recorded as AG-348; AG-348 sulfate hydrate; Mitapivat Sulfate; Mitapivat sulfate
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2027-02-01Day | MitapivatAgios Pharmaceuticals, Inc. · AGIO | Company-disclosed PDUFA goal dateAnnounced review target | sickle cell disease | Open original sourceRead source excerptWe submitted a supplemental New Drug Application, or sNDA, for the U.S. accelerated approval of mitapivat in sickle cell disease, or SCD, in May 2026, which was accepted with priority review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-02-01Day | MitapivatAgios Pharmaceuticals, Inc. · AGIO | Company-disclosed PDUFA goal dateAnnounced review target | SCD | Open original sourceRead source excerptWe submitted an sNDA for the U.S. accelerated approval of mitapivat in SCD in May 2026, which was accepted with priority review by the FDA and granted a PDUFA goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-02-01Day | MitapivatAgios Pharmaceuticals, Inc. · AGIO | Company-disclosed PDUFA goal dateAnnounced review target | sickle cell disease | Open original sourceRead source excerptNew PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |